Literature DB >> 9655471

Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model.

D M Ashley1, J H Sampson, G E Archer, L P Hale, D D Bigner.   

Abstract

We have previously reported that local secretion of either TNF-alpha or TGF beta1 by intracerebral SMA-560 malignant glioma tumor cells can reduce or eliminate tumor growth in mice. However, the use of TNF-alpha, while improving the overall survival of tumor bearing animals, was associated with early toxic deaths due to cerebral edema. In the present study, we demonstrate that TNF-alpha induces apoptosis of the SMA 560 cell line, as does TGF beta1, and that these two cytokines act in an additive fashion to enhance apoptosis and thus, to inhibit SMA 560 cell growth in vitro. Next, we show that the production of TGF beta1 when added to TNF-alpha production by central nervous system tumors in vivo abrogates any early deaths seen due to TNF-alpha toxicity and leads to a larger percentage of animals surviving CNS tumor challenge. Finally, we demonstrate that the production of TGF beta1 by tumor cells is associated with the abolition of tumor-associated cerebral edema in both TNF-alpha and in non-TNF-alpha producing tumors. These results are important for the development of effective and less toxic therapies for brain tumors, as well as for examining the pathogenesis of tumor-related cerebral edema.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655471     DOI: 10.1016/s0165-5728(98)00017-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  5 in total

1.  Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.

Authors:  Elizabeth K Hellums; James M Markert; Jacqueline N Parker; Bin He; Bernard Perbal; Bernard Roizman; Richard J Whitley; Catherine P Langford; Suman Bharara; G Yancey Gillespie
Journal:  Neuro Oncol       Date:  2005-07       Impact factor: 12.300

Review 2.  Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.

Authors:  Ting-Wei Yu; Ho-Yen Chueh; Ching-Chou Tsai; Cheng-Tao Lin; Jiantai Timothy Qiu
Journal:  Hum Vaccin Immunother       Date:  2016-08-25       Impact factor: 3.452

3.  Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.

Authors:  Timothy F Witham; Lorissa Villa; Tianbing Yang; Ian F Pollack; Hideho Okada; Paul D Robbins; William H Chambers
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

4.  Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.

Authors:  Maurizio Ghisoli; Minal Barve; Reva Schneider; Robert Mennel; Carl Lenarsky; Gladice Wallraven; Beena O Pappen; John LaNoue; Padmasini Kumar; Derek Nemunaitis; Alyssa Roth; James Nemunaitis; Sam Whiting; Neil Senzer; Frederick A Fletcher; John Nemunaitis
Journal:  Mol Ther       Date:  2015-03-19       Impact factor: 11.454

Review 5.  Duality of Interactions Between TGF-β and TNF-α During Tumor Formation.

Authors:  Zhi-Wei Liu; Yi-Ming Zhang; Li-Ying Zhang; Ting Zhou; Yang-Yang Li; Gu-Cheng Zhou; Zhi-Ming Miao; Ming Shang; Jin-Peng He; Nan- Ding; Yong-Qi Liu
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.